OutPost Bio, a London- and Boston-based BioTech research startup with a focus on making human microbiology computable, has raised €2.9 million ($3.5 million) in a pre-Seed funding round to accelerate its experimental and modelling platforms.
The round was co-led by Merantix Capital and Seedcamp, with participation from OpenSeed VC, Defined, and strategic family offices and angel investors.
“We’re building the most comprehensive dataset in human microbiology. Microbial communities can dramatically alter drugs and other interventions, yet this layer has been largely ignored because the data hasn’t existed at scale. For the first time, we can move beyond correlations to reveal causal pathways,” said Dr Jenny Yang, co-founder and CEO of Outpost Bio.
OutPost Bio was founded in 2025 by Dr Yang and Alex Merwin. Dr Yang is an Oxford PhD and a former Marie Curie Fellow with a background in clinical machine learning. Co-Founder and COO Merwin is the former Head of Growth for Health & Bio Startups at AWS.
The company claims to be decoding the hidden interactions that drive human biology. According to OutPost Bio, Human microbiology is one of the most complex and data-rich fields in biology, and R&D teams struggle to translate this complexity into actionable insights. The startup claims that most biological frontier models are built around parts encoded in human DNA, but real biology emerges from interactions across multiple systems. Outpost Bio notes that its platform addresses this gap by building frontier models at the interaction layer that focus on human microbiology.
Its Lab-in-the-Loop platform integrates automated experimentation with machine learning, creating a closed feedback loop in which models learn from experiments and guide what is tested next. “This approach generates proprietary, human-derived functional data at scale, helping pharma partners de-risk clinical development, design safer formulations, and build regulatory evidence. Beyond pharma, food and consumer companies can test how prebiotics, botanicals, and other ingredients reshape microbial communities,” mentioned the company in the press release.
It claims to enable any partner developing molecules that go into or onto humans to predict microbe-mediated metabolism, toxicity, and response; thereby making human microbiology computable for the first time.
“What took decades to build for earlier biological models can now be achieved in years. Faster wet-lab data generation, lower sequencing costs, and more powerful machine learning make this the right moment to build predictive models of the microbes that live within and on us,” said Adrian Locher, co-founder and General Partner at Merantix Capital.
With the fresh capital, OutPost Bio aims to unlock new ways to design drugs, ingredients, and consumer health products by boosting its experimental and modelling platforms.
Read the orginal article: https://www.eu-startups.com/2026/03/female-led-biotech-startup-outpost-bio-raises-e2-9-million-to-make-human-microbiology-computable/
